Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Education  





2 Academic career  





3 Academic service  



3.1  Awards  







4 Works  



4.1  Research  







5 Publications  



5.1  Peer-reviewed journal articles  





5.2  Reviews  





5.3  Books  







6 References  





7 External links  














Scott Waldman







Add links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Scott Waldman
Alma materStanford Medical School
University at Albany, SUNY
Scientific career
FieldsBiomedical science
InstitutionsJefferson Medical College

Scott A. Waldman is an MD and biomedical scientistatSidney Kimmel Medical College of Thomas Jefferson University, where he is the Samuel M.V. Hamilton Professor of Medicine, and also tenured professor and chair of the Department of Pharmacology & Experimental Therapeutics. He is author of a pharmacology textbook, and former chief editorofClinical Pharmacology & Therapeutics. He is known for his work in atrial natriuretic factor intracellular signaling through guanylate cyclase (GC), and the relation of Guanylyl cyclase C (GC-C) to the pathogenesisofcolorectal cancer. Also for his hypotheses concerning the roles of intestinal paracrine hormones (uroguanylin, guanylin) in satiety, obesity and cancer risk.[1][2] Waldman also holds a concurrent position as adjunct professor at the University of Delaware, School of Health Sciences.[3][4][5][6]

Education[edit]

Waldman was born in Brooklyn, New York on October 22, 1953. He completed a BS degree in biology from the State University of New York at Albany in 1975, followed by a Ph.D. degree in Human Anatomy from Thomas Jefferson University, Philadelphia (1980), where he worked at the Daniel Baugh Institute of Anatomy.[6] He completed postdoctoral fellowships in pharmacology first at University of Virginia (1981) and then at Stanford University (1983) with Nobel laureate Ferid Murad who acknowledged him as a major contributor in his Nobel lecture.[7] He then attended medical school, and graduated as an MD from Stanford University, Palo Alto (1987). He then had his internship (1987–1988) and clinical residency (1988–1990) in the department of medicine, Stanford University Hospital, Palo Alto.

Academic career[edit]

After his clinical training he became an assistant professor in the Division of Clinical Pharmacology in the department of medicine of Thomas Jefferson University in 1990. Since then he has remained at Jefferson Medical College, where he has stepped up the academic ladder to Samuel M.V. Hamilton Professor of Medicine (since 1998), and tenured professor and chair of the Department of Pharmacology and Experimental Therapeutics (since 2005).

At Jefferson, he has acted as director of the Jefferson Center for Individualized Medicine (2011–2015), Since 2010 he has also been associate dean of clinical and translational sciences at Jefferson Medical College (2010–2016), and vice president of clinical and translational research at Thomas Jefferson University (2010–2016). Since 2012 Waldman has held a concurrent position as an adjunct professor at the School of Health Sciences of the University of Delaware. He is also director of the Gastrointestinal Malignancies Program at the Sidney Kimmel Cancer Center of Thomas Jefferson University. From 2017 to 2020, Waldman was a visiting professor at the Xuzhou Cancer Hospital, Xuzhou, China.

From 1983 to 1990 Waldman was a staff pharmacologist at the Veterans Administration Medical Center, Palo Alto. From 1991 to 1997 he was the medical director of the Clinical Research Unit at Thomas Jefferson University Hospital, where he now is an attending physician.

Institutional profiles with details of Waldman's career are visible on the internet.[4][5][8]

Academic service[edit]

Waldman has lent academic service by his participation in committees of institutions such as NIH and FDA, in areas like clinical pharmacology training, translational research, and extramural activities.[9][10][11]

Awards[edit]

Works[edit]

Research[edit]

His early career was devoted to characterize the receptor-mediated responses to atrial natriuretic peptide (ANP) in vascular smooth muscle and other cell types, especially its stimulation of guanylyl cyclase to cause the intracellular accumulation of cGMP in the context of vasodilatory phenomena.[16] His subsequent studies on the ANP-like stimulation of guanylyl cyclase by enterotoxins[17] eventually led to new research venues into the study of guanylyl cyclase C[18] and its role in the pathogenesis of colorectal cancer.[19]

Recently, Waldman has extensively explored concepts surrounding the role of membrane-bound GUCY2C receptors lining the gastrointestinal tract in relation to the homeostatic regulation of the crypt-surface axis by paracrine hormones uroguanylin and guanylin.[20] His recent research includes the experimental targeting of such receptors in various ways for the treatment of inflammatory bowel disease and colorectal neoplasias,[21][22][23] including (under his leadership) a phase-I clinical trial to test a recombinant vaccine against colorectal cancer aimed to immunize against GUCY2C receptors.[24][25]

Publications[edit]

He was the former chief editorofClinical Pharmacology & Therapeutics[26]

Peer-reviewed journal articles[edit]

Waldman has published over 300 research articles in peer-reviewed journals.[27] His most cited articles are:

Reviews[edit]

Waldman has authored over 50 research review articles.[27] His most cited reviews are:

Books[edit]

Together with Andre Terzic, in 2009 Waldman was co-editor of the multi-author textbook Pharmacology and Therapeutics: Principles to Practice, ISBN 978-1-4160-3291-5,  (Saunders-Elsevier)

References[edit]

  1. ^ Iyer, Shweta (2014-10-10). "Loss Of This Hormone Could Up Your Chance Of Colon Cancer". Medical Daily. Retrieved 2020-08-15.
  • ^ Blomain, Erik S.; Merlino, Dante J.; Pattison, Amanda M.; Snook, Adam E.; Waldman, Scott A. (2016). "Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer". Molecular Pharmacology. 90 (3): 199–204. doi:10.1124/mol.115.103192. ISSN 1521-0111. PMC 4998665. PMID 27251363.
  • ^ "Waldman, Scott". www.jefferson.edu. Retrieved 2020-08-15.
  • ^ a b c "2015 Award Winners". Default. Retrieved 2020-09-14.
  • ^ a b "Scott Waldman Named a 2017 Fellow of the National Academy of Inventors | Sidney Kimmel Cancer Center". sidneykimmelcancercenter.jeffersonhealth.org. Retrieved 2020-09-14.
  • ^ a b "Scott Arthur Waldman, MD, PhD, FCP, FAHA, FNAI Curriculum Vitae". www.fda.gov. Retrieved 13 August 2020.
  • ^ https://www.nobelprize.org/uploads/2018/06/murad-lecture.pdf
  • ^ a b "Rawls Palmer Progress in Medicine Award Presented to Dr. Scott A. Waldman - Thomas Jefferson University". www.jefferson.edu. Retrieved 2020-09-13.
  • ^ "Clinical Pharmacology Postdoctoral Research Training Program Institutions". www.nigms.nih.gov. Retrieved 2020-09-13.
  • ^ "Division of Extramural Activities Annual Report 2016" (PDF). nih.gov. Retrieved 13 September 2020.
  • ^ "FDA Meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee". fda.gov. Retrieved 13 September 2020.
  • ^ "Henry W. Elliott Distinguished Service Award" (PDF). ascpt.org. Retrieved 13 September 2020.
  • ^ "Scott A. Waldman, MD, PhD, FCP". PhRMA Foundation. Retrieved 2020-09-13.
  • ^ "2017 NAI Fellows" (PDF). academyofinventors.org. Retrieved 13 September 2020.
  • ^ "2020 Fellows". Default. Retrieved 2020-09-13.
  • ^ "My NCBI Collection 59895250". PubMed. Retrieved 2020-08-14.
  • ^ "My NCBI Collection 59895304". PubMed. Retrieved 2020-08-14.
  • ^ "My NCBI Collection 59895338". PubMed. Retrieved 2020-08-14.
  • ^ "My NCBI Collection 59895311". PubMed. Retrieved 2020-08-14.
  • ^ Waldman, Scott A.; Camilleri, Michael (2018). "Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders". Gut. 67 (8): 1543–1552. doi:10.1136/gutjnl-2018-316029. ISSN 1468-3288. PMC 6204952. PMID 29563144.
  • ^ Rappaport, Jeffrey A.; Waldman, Scott A. (2018). "The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia". Frontiers in Oncology. 8: 299. doi:10.3389/fonc.2018.00299. ISSN 2234-943X. PMC 6091576. PMID 30131940.
  • ^ Stem, Jonathan; Flickinger, John C.; Merlino, Dante; Caparosa, Ellen M.; Snook, Adam E.; Waldman, Scott A. (2019). "Therapeutic targeting of gastrointestinal cancer stem cells". Regenerative Medicine. 14 (4): 331–343. doi:10.2217/rme-2018-0146. ISSN 1746-076X. PMC 6886570. PMID 31025613.
  • ^ Pattison, Amanda M.; Barton, Joshua R.; Entezari, Ariana A.; Zalewski, Alicja; Rappaport, Jeff A.; Snook, Adam E.; Waldman, Scott A. (2020-06-28). "Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity". Cancer Biology & Therapy. 21 (9): 799–805. doi:10.1080/15384047.2020.1779005. ISSN 1555-8576. PMC 7515455. PMID 32594830. S2CID 220258118.
  • ^ "Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 4 April 2017. Retrieved 2020-08-15.
  • ^ Ae, Snook; Tr, Baybutt; B, Xiang; Ts, Abraham; Jc, Flickinger; T, Hyslop; T, Zhan; Wk, Kraft; T, Sato (2019-04-23). "Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients". Journal for Immunotherapy of Cancer. 7 (1): 104. doi:10.1186/s40425-019-0576-2. PMC 6477737. PMID 31010434.
  • ^ "ASCPT News". Clinical Pharmacology & Therapeutics. 84 (6): 648–652. 2008. doi:10.1038/clpt.2008.227. ISSN 0009-9236. S2CID 221604444.
  • ^ a b "Scott Waldman". scholar.google.com. Retrieved 2022-03-05.
  • ^ a b c d e "Scott Waldman - Google Académico". scholar.google.es. Retrieved 2020-09-13.
  • ^ Lucas, K. A.; Pitari, G. M.; Kazerounian, S.; Ruiz-Stewart, I.; Park, J.; Schulz, S.; Chepenik, K. P.; Waldman, S. A. (2000). "Guanylyl cyclases and signaling by cyclic GMP". Pharmacological Reviews. 52 (3): 375–414. ISSN 0031-6997. PMID 10977868.
  • ^ Waldman, S. A.; Murad, F. (1987). "Cyclic GMP synthesis and function". Pharmacological Reviews. 39 (3): 163–196. ISSN 0031-6997. PMID 2827195.
  • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Scott_Waldman&oldid=1208884252"

    Categories: 
    Living people
    1953 births
    Stanford University School of Medicine alumni
    University at Albany, SUNY alumni
    Jefferson Medical College faculty
    Scientists from Brooklyn
    Fellows of the American Society for Pharmacology and Experimental Therapeutics
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Articles with hCards
    Articles with Google Scholar identifiers
     



    This page was last edited on 19 February 2024, at 10:03 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki